A national, phase II clinical trial examining the effects of resveratrol on individuals with mild to moderate dementia due to Alzheimer's disease has begun as more than two dozen academic institutions recruit volunteers in the coming months. R. Scott Turner, M.D., Ph.D., director of Georgetown University Medical Center's Memory Disorders Program, is the lead investigator for the national study.
Resveratrol is a compound found in red grapes, red grape juice, red wine, chocolate, tomatoes and peanuts. Pre-clinical and pilot clinical research studies suggest that resveratrol may prevent diabetes, act as a natural cancer fighter, ward off cardiovascular disease, and prevent memory loss, but there has been no large definitive study of its effects in humans.
The risk of all of these diseases increases with aging. Animal studies suggest that resveratrol may impede molecular mechanisms of aging. Human population studies suggest several health benefits from modest daily consumption of red wine, but the mechanisms of action in the body are unknown.
"Most resveratrol studies showing any health benefits have been conducted in animal models, such as mice, and with doses that far exceed intake from sipping wine or nibbling on chocolate," says Turner. "With this clinical trial, we'll find out if daily doses of pure resveratrol can delay or alter memory deterioration and daily functioning in people with mild to moderate dementia due to Alzheimer's."
"During this study, we will also test whether resveratrol improves glucose and insulin metabolism in older individuals -- although those who already have diabetes will not be included in this study."
Resveratrol is not approved by the Food and Drug Administration for the treatment of Alzheimer's. It is not known if resveratrol can change the course of the disease.
Not everyone who enrolls in the study will receive resveratrol. Half of the participants will receive a placebo (a sugar pill made to look like the resveratrol pill) to allow researchers to more objectively test the benefits of resveratrol. Neither the patient nor the clinical staff will know if the study participant is receiving the placebo or resveratrol until the end of the study.
"This is the gold-standard for conducting a clinical study because it allows us to objectively determine if resveratrol is offering any benefits," explains Brigid Reynolds, NP, lead investigator for the study at Georgetown.
In addition, the phase II study will examine the safety and tolerability of resveratrol administered twice daily with a dose increase planned at three-month intervals, she says.
According to the National Institute of Aging, more than 5.3 million people in the U.S. are suffering from Alzheimer's, and every 70 seconds, another person develops this disease. In Washington, DC, more than 9,000 people aged 65 and older are currently living with Alzheimer's.
The resveratrol study will be conducted at 26 U.S. academic institutions that are affiliated with the Alzheimer's Disease Cooperative Study. Patients who volunteer for the study cannot be enrolled in another clinical trial during the study period. They will also be asked to abstain from eating or drinking large quantities of foods or beverages that contain resveratrol, and abstain from taking dietary supplements containing resveratrol.
Each patient will be in the study for a twelve-month period and will require a study partner (spouse, friend or caregiver) to visit the Georgetown University Medical Center 10 times over the course of that year. Participants must be willing and able to undergo two lumbar punctures (a procedure where a needle is inserted into the lower spine to collect fluid), three MRI scans of the brain, and blood and urine tests during the course of the study.
The research is sponsored by the Alzheimer's Disease Cooperative Study (ADCS), through a grant from the National Institute on Aging (NIA). Turner and Reynolds report no personal financial interests related to the study.
To learn more about the resveratrol study or other Alzheimer's studies underway at Georgetown, contact Kelly Behan in the GUMC Memory Disorders Program by calling (202) 687-0413 or by emailing her at firstname.lastname@example.org. Information is also available at memory.georgetown.edu. Georgetown study participants must speak English.
About Georgetown University Medical Center
Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC's mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization (BGRO), which accounts for the majority of externally funded research at GUMC including a Clinical Translation and Science Award from the National Institutes of Health. In fiscal year 2010-11, GUMC accounted for 85 percent of the university's sponsored research funding.
Karen Mallet | EurekAlert!
Self-organising system enables motile cells to form complex search pattern
07.05.2019 | Westfälische Wilhelms-Universität Münster
Mouse studies show minimally invasive route can accurately administer drugs to brain
02.05.2019 | Johns Hopkins Medicine
Physicists at the University of Basel are able to show for the first time how a single electron looks in an artificial atom. A newly developed method enables them to show the probability of an electron being present in a space. This allows improved control of electron spins, which could serve as the smallest information unit in a future quantum computer. The experiments were published in Physical Review Letters and the related theory in Physical Review B.
The spin of an electron is a promising candidate for use as the smallest information unit (qubit) of a quantum computer. Controlling and switching this spin or...
Engineers at the University of Tokyo continually pioneer new ways to improve battery technology. Professor Atsuo Yamada and his team recently developed a...
With a quantum coprocessor in the cloud, physicists from Innsbruck, Austria, open the door to the simulation of previously unsolvable problems in chemistry, materials research or high-energy physics. The research groups led by Rainer Blatt and Peter Zoller report in the journal Nature how they simulated particle physics phenomena on 20 quantum bits and how the quantum simulator self-verified the result for the first time.
Many scientists are currently working on investigating how quantum advantage can be exploited on hardware already available today. Three years ago, physicists...
'Quantum technologies' utilise the unique phenomena of quantum superposition and entanglement to encode and process information, with potentially profound benefits to a wide range of information technologies from communications to sensing and computing.
However a major challenge in developing these technologies is that the quantum phenomena are very fragile, and only a handful of physical systems have been...
Working group led by physicist Professor Ulrich Nowak at the University of Konstanz, in collaboration with a team of physicists from Johannes Gutenberg University Mainz, demonstrates how skyrmions can be used for the computer concepts of the future
When it comes to performing a calculation destined to arrive at an exact result, humans are hopelessly inferior to the computer. In other areas, humans are...
29.04.2019 | Event News
17.04.2019 | Event News
15.04.2019 | Event News
23.05.2019 | Materials Sciences
23.05.2019 | Materials Sciences
23.05.2019 | Physics and Astronomy